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Abstract
Background: This study investigated changes over time in the epidemiology of extended-spectrum β-lactamase
(ESBL) producing Escherichia coli within a single equine referral hospital in the UK. Faecal samples were collected
from hospitalised horses in 2008 and 2017, processed using selective media and standard susceptibility laboratory
methods. A novel real-time PCR with high resolution melt analysis was used to distinguish blaCTX-M-1 and blaCTX-M-15
within CTX-M-1 group.
Results: In 2008, 457 faecal samples from 103 horses were collected, with ESBL-producing E. coli identified in 131
samples (28.7, 95% CI 24.6–33.1). In 2017, 314 faecal samples were collected from 74 horses with ESBL-producing E.
coli identified in 157 samples (50.0, 95% CI 44.5–55.5). There were 135 and 187 non-duplicate ESBL-producing
isolates from 2008 and 2017, respectively. In 2008, 12.6% of isolates belonged to CTX-M-1 group, all carrying
blaCTX-M-1, whilst in 2017, 94.1% of isolates were CTX-M-1 group positive and of these 39.2 and 60.8% of isolates
carried blaCTX-M-1 and blaCTX-M-15, respectively. In addition, the prevalence of doxycycline, gentamicin and 3rd
generation cephalosporin resistance increased significantly from 2008 to 2017 while a decreased prevalence of
phenotypic resistance to potentiated sulphonamides was observed.
Conclusions: The real-time PCR proved a reliable and high throughput method to distinguish between blaCTX-M-1
and blaCTX-M-15. Furthermore, its use in this study demonstrated the emergence of faecal carriage of CTX-M-15 in
hospitalised horses, with an increase in prevalence of ESBL-producing E. coli as well as increased antimicrobial
resistance to frequently used antimicrobials.
Keywords: ESBL-producing E. coli, Melt curve analysis, Multidrug resistance, High resolution melt, Real time PCR,
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Background
Extended spectrum β-lactamase (ESBL)-producing
Escherichia coli are typically resistant to extended
spectrum cephalosporins and monobactams (aztreo-
nam), as well as non-β-lactam agents. These bacteria are
of increasing concern as ESBL encoding genes are usu-
ally harboured on plasmids, which co-harbour multiple
resistance genes [1] leading to multi-drug resistance
(MDR, defined as resistance to 3 or more antimicrobial
classes). Clinical infections caused by MDR bacteria are
particularly difficult to treat and are a leading cause of
morbidity and mortality in human and veterinary medi-
cine [2, 3]. The initially identified β-lactamase enzymes
such as TEM and SHV are now becoming less prevalent
in ESBL-producing E. coli, while CTX-M is now the most
predominant mechanism in both humans and animals [4].
Almost 170 distinct ESBL CTX-M β-lactamases have been
identified mostly in Enterobacteriaceae, including in
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Escherichia, Klebsiella and Enterobacter species [5]. The
CTX-M family includes a complex group of enzymes
which have been classified into five different groups;
CTX-M-1, 2, 8, 9 and 25 based on their amino acid
sequences [4]. These enzymes are able to efficiently hydro-
lyse cefotaxime and in some cases ceftazidime (CTX-M-
15, CTX-M-16, CTX-M-27) [6, 7].
The worldwide emergence of the blaCTX-M-15 gene
(belonging to CTX-M-1 group) during the last two
decades in humans is of concern; particularly as it is
often associated with the pandemic O25/ST131 E. coli
clone [8], which belongs to the highly virulent phylo-
genetic group B2 and often harbours the multidrug-
resistant IncFII plasmids [9]. In ST648 E. coli strains
in human and companion animal studies, a high pro-
portion of blaCTX-M-15 has been identified [10]. The
now widespread dissemination of CTX-M-15-produ-
cing E. coli could have two explanations. Correspond-
ing plasmids encoding the blaCTX-M-15 gene are being
transferred via horizontal transfer to multiple lineages
[11], or alternatively the strains may be spreading by
clonal expansion [12].
Several studies have reported blaCTX-M-1 (also belong-
ing to group 1) to be the most common ESBL-gene in E.
coli in horses [13–15], however one study also identified
a low prevalence of other blaCTX-M genes [13]. CTX-M-
15-producing E. coli has been identified in clinical iso-
lates from horses in Germany [10, 16] and has been
infrequently identified in E. coli from hospitalised horses
in Holland [13].
Although conventional PCR assay can be used to de-
termine which group a CTX-M enzyme belongs to,
Sanger sequencing has, to date, been required to deter-
mine the CTX-M genotype [17], which has proved costly
and time consuming, hence previous studies have often
only classified genes to the group level. Whole genome
or next generation sequencing, whilst also identifying
genes and genetic contexts is still too expensive for rou-
tine surveillance. High resolution melt (HRM) analysis is
an end-point real-time PCR detection method that dif-
ferentiates amplicons based on their melt profile. Here
we describe this method using novel primers to distin-
guish between different blaCTX-M genes within group 1
based on their different melt point. While there are
studies reporting the change in antimicrobial resistance
(AMR) patterns in equine clinical isolates over time,
there are no studies investigating carriage of AMR genes
in hospitalised horse populations over time. The aims of
the present study were to investigate the trend in AMR
patterns over time, to determine the prevalence of
blaCTX-M-1 and blaCTX-M-15 genotypes within CTX-M-1
group and to compare changes in phenotype and geno-
type of ESBL-producing E. coli over time within a single
equine hospital in the UK.
Results
In total 771 faecal samples were collected. In 2008 co-
hort, 457 faecal samples from 103 horses were collected
with ESBL-producing E. coli identified in 131 samples
(28.7, 95% CI 24.6–33.1) from 49 horses (47.6, 95% CI
37.7–57.6). In 2017 cohort, 314 faecal samples were col-
lected from 72 horses with ESBL-producing E. coli iden-
tified in 157 samples (50.0, 95% CI 44.5–55.5) of
samples from 47 horses (65.3, 95% CI 53.8–75.3). In the
2008 and 2017 cohorts, antimicrobials had been admin-
istered in the previous 7 days prior to sampling in 51.1%
(67/131) and 67.5% (106/157) of samples respectively,
where an ESBL-producer was identified. Antimicrobials
had been administered in the previous 7 days in 32.5%
(106/326) and 47.1% (74/157) of samples in the 2008
and 2017 cohorts respectively where no ESBL-producer
was identified. Overall use of highest priority critically
important antimicrobials (HPCIAs) was low and in-
cluded 5.8% (6/103) horses (3 enrofloxacin and 3 ceftio-
fur) in the 2008 cohort and 9.7% (7/72) horses (2
enrofloxacin and 5 ceftiofur) in the 2017 cohort. Surgery
was performed during hospitalisation in 53.4% (55/103)
and 45.8% (33/72) of horses in the 2008 and 2017 co-
horts respectively. The breakdown of type of cases in the
two cohorts is shown in Table 1.
There were 135 non-duplicate ESBL isolates from
2008 cohort and 187 non-duplicate ESBL isolates from
2017 cohort. The HRM analysis demonstrated high spe-
cificity during the pilot evaluation, with no non-specific
amplification generated when testing a panel of 17 non-
target ESBL producers. The assay was 100% accurate at
differentiating blaCTX-M-1 and blaCTX-M-15 compared
with sequencing, across 44 isolates, indicating 100%
agreement (Fig. 1).
Conventional PCR analysis demonstrated a reduction
in carriage of blaTEM and blaSHV genes of approximately
50% between the two cohorts and an increase in carriage
of blaCTX-M by 37.8%. However, the blaTEM and blaSHV
Table 1 Clinical case type in the two cohorts. GI non-surgical
cases included colic cases which were treated medically.
Medical cases included general medical cases such as
ophthalmology, respiratory and non-GI cases. Musculoskeletal
cases included mainly lameness investigation and orthopaedic
surgical cases. Soft tissue cases included mass removals, dental/
sinusitis investigations and surgical airway cases. GI =
Gastrointestinal
Case type 2008 (n = 103) 2017 (n = 72)
GI non-surgical 5 12
GI surgical 3 8
Medical 35 9
Musculoskeletal 29 27
Soft tissue 31 16
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genes were not further confirmed in either cohort to de-
termine if they were ESBL variants. In the 2008 cohort
isolates, only 12.6% (n = 17) were CTX-M-1 group posi-
tive, all of which identified as blaCTX-M-1 using HRM
analysis. In 2017 cohort isolates, 94.1% (n = 176) were
CTX-M-1 group positive and of these 39.2% (n = 69)
identified as blaCTX-M-1 and 60.8% (n = 107) as
blaCTX-M-15 using HRM analysis. All 107 isolates identi-
fied as CTX-M-15 producers were negative for 025 and
ST131 on PCR assay. There was a significant increase in
carriage of qnr A (11.9%) and a small non-significant de-
crease in carriage of qnr B (− 1.26%) and qnr S (− 1.3%).
The change in genotype between the two cohorts is
shown in Table 2.
Furthermore, there was an increased variability in
phenotypic resistance in the ESBL-producing E. coli be-
tween the two cohorts. Some of these changes were not
significant (amoxicillin, enrofloxacin and MDR), while there
was a significant increase in resistance to doxycycline, gen-
tamicin and 3rd generation cephalosporins and an increase
in susceptibility to trimethoprim-sulfamethoxazole. The
antimicrobial resistance in non-duplicate ESBL-producing
E. coli is shown in Table 3.
Discussion
According to our current knowledge this study is the
first to identify blaCTX-M-15 in ESBL-producing E. coli in
horses at an equine hospital in the UK, as well as report-
ing a significant increase in prevalence of CTX-M-1 and
a reduction in CTX-M-9 β-lactamase producing E. coli
isolates in the same hospital over a decade. The study
also demonstrated a significant increase in prevalence of
overall carriage of ESBL-producing E. coli and their re-
sistance to commonly used antimicrobials in horses, in
particular, an increase in resistance to doxycycline, gen-
tamicin and 3rd generation cephalosporins.
This is also the first study using HRM analysis to dis-
tinguish between blaCTX-M-1 and blaCTX-M-15. The assay
uses a single set of primers to amplify a 213 bp region
common to group 1 blaCTX-M- genes, which contains six
variant bases blaCTX-M-1 and blaCTX-M-15 that are highly
conserved. The presence of these six variants results in a
Fig. 1 High resolution melt analysis results for four blaCTX-M-1 carrying isolates, four blaCTX-M-15 carrying isolates and a no template control. The
calling threshold and calling bins for automatic genotyping are indicated by the horizontal and vertical lines, respectively
Table 2 The prevalence and change of genotype in ESBL-producing E. coli isolated from hospitalised horses in two different cohorts
from the same equine hospital sampled 10 years apart
Genotype (322) 2008 cohort (n = 135) Prevalence (95% CI) 2017 cohort (n = 187) Prevalence (95% CI) Change (%) P -value
blaSHV (105) 86 63.7 (55.3–71.3) 19 10.2 (6.6–15.3) −53.5 < 0.001
blaTEM (183) 116 85.9 (79.1–90.8) 67 35.8 (29.3–42.9) −50.1 < 0.001
blaCTX-M (253) 76 56.3 (47.9–64.4) 177 94.6 (90.4–97.1) + 37.8 < 0.001
blaCTX-M Gr1 (193) 17 12.6 (8.0–19.2) 176 94.1 (89.8–96.7) + 81.5 < 0.001
CTX-M-1 (86) 17 100 (81.6–100) 69 39.2 (32.3–46.6) −60.8 < 0.001 †
CTX-M-15 (107) 0 0 (0–18.4) 107 60.8 (53.4–67.7) + 60.8
blaCTX-M Gr2 (10) 9 6.7 (3.6–12.2) 1 0.5 (0–3.0) −6.1 0.002 †
blaCTX-M Gr9 (50) 50 37.0 (29.4–45.4) 0 0.0 (0.0–2.0) −37.0 < 0.001 †
qnr A (27) 2 1.5 (0.4–5.2) 25 13.4 (9.2–19.0) + 11.9 < 0.001 †
qnr B (48) 30 22.2 (16.0–30.0) 18 9.6 (6.2–14.7) −12.6 0.003
qnr S (19) 9 6.7 (3.6–12.2) 10 5.4 (2.9–9.6) − 1.3 0.8
P-value provided for Chi-squared test apart from where † indicates use of Fisher’s Exact Test
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~ 0.5 °C difference in the melt temperature, allowing dis-
crimination of these genes. The ability to differentiate
these genes without the requirement of any post PCR
processing or sequencing provides faster results and
higher throughput, will be of great benefit in studies in-
volving large sample numbers.
There was 100% agreement between the HRM analysis
and the sequencing results in the 44 pilot samples, indi-
cating complete accuracy. HRM analysis has been used
previously for applications including bacterial speciation,
and the detection of resistance genes [18], and has po-
tential both as a diagnostic test and epidemiological sur-
veillance tool. In addition to genotyping assays, HRM
analysis has also been utilised to enable highly multi-
plexed assays, without the use of costly hydrolysis probes
[18]. HRM analysis typically has a lower analytical sensi-
tivity than probe-based PCRs, but this is not a drawback
when testing high copy number samples, such as bacter-
ial colonies. Whilst sequencing provides a greater level
of resolution, HRM analysis results were sufficient to de-
termine the gene carried by the CTX-M producers,
allowing greater number of samples to be tested during
the study than if relying solely on sequencing.
Previous studies have identified blaCTX-M-15 in five
clinical samples from horses in Germany [10, 16], as well
as low frequency carriage (2/123 isolates, 1.6%) in hospi-
talised horses in Holland [13]. Our study is the first
study to report CTX-M-15 β-lactamase as the predom-
inant enzyme in ESBL-producing E. coli carried by
horses. The emergence of CTX-M-15 β-lactamase during
this 10 year period in this equine hospital is in line with
the global trend of the spread of this enzyme in humans
[19] and more recently in veterinary studies [16, 20, 21].
CTX-M-15 producing ST131 has also been identified in a
dog in Portugal [22], and in three canine clinical isolates
in the UK [23] but has yet to be identified in horses, which
is supported by the results from the current study. While
ST131 is rare in veterinary studies [20, 22], ST648
(phylotype D) [10] and ST410 (phylotype A) [20] have
more frequently been reported from clinical and environ-
mental hospital samples. ST410 has been recently de-
scribed as a new international high-risk clone [24], whilst
ESBL-producing ST648 strains have also been observed
globally in human patients, as well as in chicken, pigs and
wild birds in Europe [25, 26]. There was also a marked dif-
ference in the carriage of CTX-M-9 group β-lactamase
producing E. coli isolates between the two cohorts; it was
the most common group present in the first study while
in the later cohort there were no CTX-M-9 ESBL-produ-
cing E. coli positive isolates identified, which is perhaps
due to the global spread if group 1 isolates (particularly
blaCTX-M-15), whilst group 9 isolates (such as blaCTX-M-9
and blaCTX-M-14), commonly found in food-producing ani-
mals [4], are becoming more scarce in the equine popula-
tion [13].
The increase in prevalence of faecal-carriage of ESBL-
producing E. coli in horses from one hospital over a dec-
ade is perhaps not a surprising finding and hospital
studies involving human patients are reporting similar
results [4]. The largest increase in antimicrobial resist-
ance between the two cohorts was to doxycycline and
this is a surprising finding as tetracycline use in this
equine hospital is low (data not shown). Oral antimicro-
bials in horses are limited to potentiated sulphonamides
(authorised) and enrofloxacin (no market authorisation),
but more recently oral doxycycline (no market author-
isation) has become a more popular treatment as it is
cost-effective and can be easily administered by the
owner at home. This increased popularity of doxycycline
in the equine community has perhaps led to a reduction
in use of potentiated sulphonamides, which may be one
reason for the change in resistance patterns in these two
antimicrobials in our study. There are more than 12
tetracycline resistance genes described in E. coli and they
include three main mechanisms; drug efflux pumps,
ribosomal protection proteins, and drug inactivation.
Table 3 Prevalence of, and change in phenotypic AMR in ESBL-producing E. coli isolated from hospitalised horses in two different
cohorts from the same equine hospital sampled 10 years apart (2008 and 2017) TMPS- Trimethoprim sulfamethoxazole, MDR -
multidrug resistance (defined as resistance to 3 or more antimicrobial classes)
Antimicrobial agent/phenotype 2008 cohort (n =
135)
Prevalence (95%
CI)
2017 cohort (n =
187)
Prevalence (95%
CI)
%
change
Total (%) P value
Amoxicillin (%) 135 100 (97.2–100) 187 100 (98.0–100) 0 322 (100) 1.0 †
Cefpodoxime (%) 130 96.3 (91.6–98.4) 187 100 (98.0–100) + 3.7 317 (98.4) 0.01†
Ceftiofur (%) 123 91.1 (85.1–94.8) 182 97.3 (93.9–98.9) + 6.2 305 (94.7) 0.03
Gentamicin (%) 118 87.4 (80.8–92.0) 181 96.8 (93.2–98.5) + 9.4 299 (92.9) 0.0026
TMPS (%) 133 98.5 (94.8–99.6) 159 85.0 (79.2–89.4) −13.5 292 (90.7) < 0.001
Doxycycline (%) 53 39.3 (31.4–47.7) 172 92.0 (87.2–95.1) + 52.7 225 (69.9) < 0.001
Enrofloxacin (%) 36 26.7 (19.9–34.7) 62 33.2 (26.8–40.2) + 6.5 98 (30.4) 0.3
MDR (%) 120 88.9 (82.5–93.2) 176 94.1 (89.8–96.7) + 5.2 296 (91.9) 0.1
P-value provided for Chi-squared test apart from where † indicates use of Fisher’s Exact Test
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Some of these genes may be plasmid mediated, in par-
ticularly tetA and tetB genes which code for efflux
pumps, and the increase in tetracycline resistance may
be due to co-existence on the same plasmid as the ESBL
genes. Further work is required to investigate such asso-
ciations, including conjugation experiments, plasmid
typing and sequencing. The hospital use of HPCIAs [27],
including third and fourth generation cephalosporins
was low in both cohorts and there was no clear reason
for the increase in prevalence of ESBL-producing E. coli
between the two cohorts. The use of third and fourth
generation cephalosporins by referring veterinarians is
unknown. However, a study in 2013 identified that third
and fourth generation cephalosporins only accounted for
3% of prescriptions and that equine veterinarians in first
opinion practice most commonly prescribe potentiated
sulphonamides [28].
Limitations of this study include the low numbers of
isolates which underwent Sanger sequencing to validate
the results from the HRM analysis, but in these 44 iso-
lates there was complete agreement. Another limitation
is that the study included only two sampling periods and
used slightly different sampling protocols; in 2008 cohort
horses were sampled every other day while in 2017 co-
hort horses were sampled daily, however this is unlikely
to affect the results as antimicrobial susceptibility testing
was repeated on the stored isolates in 2018.
Conclusions
The present study demonstrates that HRM analysis is a
reliable and low-cost method and can be used to distin-
guish between CTX-M-1 and CTX-M-15 β-lactamase
producers in group 1 positive isolates from a conven-
tional PCR assay without the need for sequencing of
PCR amplicons. Our study also demonstrated an emer-
gence of carriage of CTX-M-15 producing E. coli isolates
in hospitalised horses in the UK. This may have public
health implications as when these horses leave the hos-
pital, they may contribute to the dissemination of ESBL-
producing E. coli in the environment. It is generally
accepted that carriage is a pre-requisite for infection and
future studies are needed to investigate the link between
faecal CTX-M-15 carriage and ESBL-producing E. coli
obtained from clinical isolates in horses in the UK.
Methods
Faecal samples were collected from two different cohorts
of hospitalised horses at a single, large referral equine
hospital in North West UK which admits approximately
1500 cases annually. Animals eligible for the study were
all horses hospitalised for at least one night in the hos-
pital. Day cases were excluded as were animals receiving
chemotherapy or radiotherapy and those in isolation.
Samples (~ 30 g) were taken from the top of a pile of
freshly passed faeces from each horse by hospital staff,
placed in sterile plastic containers and transported to
the laboratory on the same site as the equine hospital. In
2008 cohort (2008–2009) faecal samples were collected
every other day during hospitalisation [29], while in
2017 cohort (2016–2017), recruited from the same hos-
pital, daily faecal samples were obtained from each horse
until the horse was discharged from hospital.
Isolation of resistant bacteria from faecal samples
E. coli isolation was performed according to a previously
described method [29]. Briefly, 2 g of faeces were placed
in a stomacher bag and 10 ml of brain heart infusion
broth was added. To screen for cephalosporin-resistant
E. coli (presumptive ESBL-producers), 0.5 ml of the fae-
cal homogenate was also added to 4.5 ml buffered pep-
tone water for aerobic incubation at 37 °C for 18–24 h.
Following overnight enrichment, 5 μl of the faecal hom-
ogenate was streaked onto a selective media [Eosin
Methylene Blue Agar (EMBA) or Harlequin agar)] con-
taining 1 μg/ml cefotaxime using a 5 μl disposable sterile
loop and incubated aerobically for 18–24 h at 37o C. On
the selective media, if present, two colonies resembling
E. coli were selected from the plate and transferred onto
nutrient agar and incubated overnight at 37 °C.
Antimicrobial susceptibility and ESBL phenotypic testing
Colonies from nutrient agar plates were suspended in
sterile water to make a suspension equivalent to 0.5
McFarland Turbidity Standard (0.5 MTS). Each isolate
suspension was then inoculated onto a Mueller Hinton
agar plates for antimicrobial susceptibility testing follow-
ing the Clinical & Laboratory Standards Institute (CLSI,
2016). Double disc diffusion tests using ceftazidime
(30 μg), cefotaxime (30 μg) and cefpodoxime (30 μg) ±
clavulanic acid was used to confirm phenotypic ESBL-
producing E. coli. Antimicrobial susceptibility testing
was performed using discs of 10 μg amoxicillin (amox),
10 μg cefpodoxime (cpd), 30 μg ceftiofur (eft), 10 μg gen-
tamicin (gent), 5 μg enrofloxacin (enf), 30 μg doxycycline
(dxt), 1.25 μg trimethoprim + 23.75 μg sulfamethoxazole
(TMPS). All microbiological media were from LabM,
UK; antimicrobial agents were from Mast Group, UK
(amox, cpd, gent, enf, dxt and tmps) or Oxoid, Basing-
stoke, UK (eft). After 16–18 h incubation at 37 °C, the
bacterial growth inhibition zone diameter (mm) for each
disc was measured. Isolates were categorised as suscep-
tible if the diameter of the zone of inhibition was greater
than the breakpoint for that drug [30], resulting in a bin-
ary outcome of susceptible or resistant. Control strain
E.coli ATCC 52922 was used for susceptibility testing.
MDR for E. coli was defined according to criteria which
excludes intrinsic resistance; aminopenicillins and 3rd
generation cephalosporins were considered separate
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classes for MDR calculations [31]. Long-term storage of
isolates was undertaken at -80 °C using Microbank™
cryovials (Pro-Lab Diagnostics U.K, Cheshire UK) and
isolates were recovered by removing a single bead from
the cryovial using sterile forceps and inoculation of the
bead onto nutrient agar for aerobic incubation at 37 °C
for 16–18 h. There was 100% recovery of frozen isolates.
All testing was performed by the same operators in
2017/2018 and the methods and interpretation criteria
were the same for the two cohorts. Samples from 2008
were initially archived and retrieved in 2018.
Genotypic analysis
Cell lysates were prepared by adding two to three col-
onies of pure 24-h cultures to 0.5 mL sterile water and
heating at 100 °C for 20 min. All isolates phenotypically
consistent with E. coli were confirmed using uidA gene
primers in a standard PCR assay [29, 32]. All isolates
confirmed as EBSL-producers using double disc diffu-
sion test were tested by conventional PCR for blaCTX-M
genes using universal blaCTX-M primers as previously de-
scribed [33]. To determine the CTX-M group, all CTX-
M positive isolates were tested using primers specific to
blaCTX-M groups 1, 2 [34] and 9 [33]. All isolates demon-
strating an ESBL-phenotype were also tested for blaTEM,
blaSHV and blaOXA encoding beta-lactamase genes [35]
and plasmid-mediated qnrA, B and S genes conferring
quinolone resistance using further multiplex PCR assays
[36].
HRM analysis
All isolates identified as carrying CTX-M-1 group ESBL
genes were categorised as blaCTX-M-1 or blaCTX-M-15 pro-
ducers using a novel HRM analysis based real time PCR
assay. Primers were designed from CTX-M-1 group se-
quences aligned in MEGA, using ClustalX. A 213 bp re-
gion was selected with the maximum variation between
blaCTX-M-1 or blaCTX-M-15 gene sequences, to allow for
the greatest Tm shift during melt analysis. Primers were
designed using Primer3 (http://primer3.ut.ee/), and
amplicon Tm was estimated using the nearest neighbour
method in OligoCalc (http://biotools.nubic.northwest-
ern.edu/OligoCalc.html). E. coli 13353 was used as a
control strain in the assay validation (CTX-M-15). The
primer details are shown in Table 4.
Reactions were carried out in the Rotor-Gene Q 6000
(Qiagen, Germany) using Type-It HRM mix (Qiagen,
Germany), and 400 nM of both forward and reverse
primers. Cycling conditions were 95 °C for 5 min,
followed by 30 cycles of 95 °C for 10 s, 58 °C for 30 s and
72 °C for 10 s. Reactions were monitored in the FAM
channel, and end point high resolution melt analysis was
carried out using the HRM channel at 0.1 °C increments
from 72 °C to 95 °C. The calling bins for blaCTX-M-1 and
blaCTX-M-15 gene were set at 84.75 °C (+/− 0.1 °C) and
85.25 °C (+/− 0.1 °C), respectively, by the predicted melt
temperatures. The specificity of the primers was
confirmed by testing against a bank of 17 non-target β-
lactamase producers, including CTX-M-9 (n = 5), CTX-
M-2 (n = 1), CTX-M-8 (n = 1) group, TEM (n = 5) and
SHV (n = 5) positive isolates. The accuracy of the melt
analysis method was validated by Sanger sequencing
(Source Bioscience, UK), where the blaCTX-M gene was
confirmed in 44 CTX-M-1 group carrying isolates (9
blaCTX-M-1, 35 blaCTX-M-15) and then testing these iso-
lates using HRM analysis.
The assay was then used to test all CTX-M-1 group
producers identified in the study. Isolates carrying
blaCTX-M-15 were tested further by conventional PCR
assay to determine whether they belonged to serogroup
O25 [37] and for markers for sequence type (ST)131
[38], representing the pandemic E. coli clone associated
with CTX-M-15 in human clinical infections [8].
Data analysis
The 95% confidence intervals around proportions were
calculated using Wilson’ Score interval [39]. Differences
in proportions between the two cohorts were compared
using a Chi-squared test. Where a comparison had less
than five in any category a Fishers exact test was used.
All analysis was performed using EpiTools [39]. A P
value of < 0.05 was regarded as significant.
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